Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vistin Pharma ASA ( (DE:VP4) ) has shared an announcement.
Vistin Pharma ASA announced it will release its third quarter and year-to-date 2025 financial results on October 31, 2025, accompanied by a conference call for shareholders and interested parties. This announcement underscores the company’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
More about Vistin Pharma ASA
Vistin Pharma is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride (API), including Direct Compressible lubricated granules. As a dedicated European Metformin producer, the company is a key supplier to leading pharmaceutical companies. Headquartered in Oslo, Norway, Vistin Pharma operates with a highly qualified team and a dedicated manufacturing facility in Kragerø.
Average Trading Volume: 19,278
Current Market Cap: NOK962.3M
Learn more about VP4 stock on TipRanks’ Stock Analysis page.